^
5ms
Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review. (PubMed, Lung Cancer)
This study affirms the efficacy of lorlatinib in patients with ALK-positive SCLC transformation harboring the V1180L mutation. Furthermore, it underscores the imperative of conducting genetic testing in patients who transition to SCLC following ALK-TKI resistance, as targeted therapies may remain efficacious if a genetic driver is identified.
Clinical • Retrospective data • Review • Clinical Trial,Phase II • Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • ALK V1180L • ALK fusion + ALK V1180L
|
Alecensa (alectinib) • Lorbrena (lorlatinib)